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INTRODUCTION
1.  Male hypogonadism definition and 
classifications
Historically, male hypogonadism (HG) – and in 
particular testosterone (T) deficiency (TD) – has been 
classified according to the site of origin of the putative 
damage to the hypothalamus-pituitary-testis (HPT) 
axis (i.e., primary and secondary) or according to the 
gonadotropin levels (i.e., hypo- or hyper-gonadotropic). 
Primary HG is hypergonadotropic and secondary HG 
is hypogonadotropic. In addition, an impaired T bio-
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A dichotomic distinction between “organic” and “functional” hypogonadism is emerging. The former is an irreversible condi-
tion due to congenital or “acquired” “organic” damage of the brain centers or of the testis. Conversely, the latter is a poten-
tially reversible form, characterized by borderline low testosterone (T) levels mainly secondary to age-related comorbidities 
and metabolic derangements, including metabolic syndrome (MetS). Life-style modifications, – here reviewed and, when 
possible, meta-analyzed –, have documented that weight-loss and physical exercise are able to improve obesity-associated 
functional hypogonadism and its related sexual symptoms. A rabbit experimental model, of MetS originally obtained in 
our lab, showed that endurance training (PhyEx) completely reverted MetS-induced hypogonadotropic hypogonadism by 
reducing hypothalamus inflammation and testis fibrosis eventually allowing for a better corpora cavernosa relaxation and 
response to sildenafil. Physicians should strongly adapt all the reasonable strategies to remove/mitigate the known conditions 
underlying functional hypogonadism, including MetS and obesity. Physical limitations, including reduced muscle mass and 
increased fat mass, along with low self-confidence, also due to the sexual problems, might limit a subject’s propensity to in-
crease physical activity and dieting. A short term T treatment trial, by improving muscle mass and sexual function, might help 
hypogonadal obese patients to overcome the overfed, inactive state and to become physically and psychologically ready for 
changing their lifestyle. 
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activity – due to alterations in the receptor status 
or in steroid free hormones – might also result in a 
hypogonadal-like syndrome [1]. This classification has 
the advantage of giving insights to the clinician on the 
possible therapeutic approaches, e.g., gonadotropins or 
T in secondary forms and only T in the primary forms 
[2,3]. However, the clinical scenario and subject pheno-
type of the HG patient is dramatically dependent upon 
timing of appearance of the TD [2]. When the deficit 
is orchestrating its effect very early on during fetal 
life, the masculine phenotype is severely compromised, 
whereas, when TD is manifested during adulthood, 
the phenotype is only minimally affected and symp-
toms and signs are often vague and unspecific. The 
most characteristic symptoms of this latter form (often 
called late onset hypogonadism or LOH) are sexual 
symptoms, including reduced sexual desire and im-
paired spontaneous and sexual-related erections [4,5]. In 
adult men older than 40 years of the European general 
population, a TD is a frequent finding (i.e., 12% and 2%, 
for secondary and primary HG, respectively). However, 
the large majority of these men do not present the 
aforementioned cluster of sexual symptoms, which are 
present in only 2% of them. According to the majority 
of Andrology Societies [6-9], and to the Endocrine Soci-
ety [3], only TD men presenting typical symptoms can 
be categorized and treated as a true HG. 
LOH, also in its symptomatic form, is often associated 
with aging and its related comorbidities, including obe-
sity, metabolic syndrome (MetS) and diabetes mellitus 
type 2 (T2DM). In particular, the latter metabolic con-
ditions increase the risk of secondary HG, whereas the 
aging process per se increases the likelihood of having 
a primary HG [10-12]. Considering that a secondary HG 
is by far more prevalent than the primary one, under-
standing the molecular mechanism(s) leading to a co-
morbidity-dependent hypothalamic-pituitary failure is 
relevant. In a minority of cases, secondary HG could be 
associated with other potentially reversible conditions, 
such as use or abuse of opiates and anabolic androgens 
as well as hyperprolactinemia [3,13]. In all these cases 
of secondary HG, the Endocrine Society suggests that 
removing the underlying noxious condition may have a 
beneficial effect on HG, along with obvious additional 
health benefits [3]. This position partially endorses a 
previous US Food and Drug Administration [14] and 
Health Canada [15] Drug Safety Notification that rec-
ommended T therapy (TTh) only in those subjects with 
proven “organic” damages to the HPT axis (organic 
HG). Similarly, the Endocrine Society of Australia 
stated that TTh is not justified in older HG men with 
comorbidities and that obese men should be firstly en-
couraged to lose weight [3]. 
2. Organic and functional hypogonadism
A clear distinction between an “organic” and a 
“functional” HG was formalized few years ago in a 
perspective article by Grossmann and Matsumoto [16]. 
Organic HG is an essentially irreversible HG, charac-
terized by specific symptoms and signs and very low 
T levels. In organic HG, TTh is supposed to result in 
expected net effects, along with a reasonable therapy 
risk, when considering benefits [16]. In contrast, “func-
tional” HG is a reversible form, with borderline low T 
levels, characterized by sexual symptoms that are only 
partially ameliorated by TTh, and, more importantly, 
with an unknown therapy risk. For “functional” HG, 
change in lifestyle and removing the underlying condi-
tion leading to the TD is the recommended strategy to 
increase endogenous T. Although this position might 
have a more than reasonable background – i.e., remov-
ing the cause of the disease and not just buffering its 
consequences – changing lifestyle is not an easy task 
to reach in everyday clinical practice. In addition, it 
should be emphasized that the large majority of sub-
jects consulting for sexual dysfunction and having 
low T can be categorized as functional HG (85%), with 
secondary HG the prevalent form, with a ratio of 5.5:1 
vs. primary HG [17]. Only 50% and 10% of primary and 
secondary HG, respectively, show an organic origin for 
the TD. In particular, the large majority of secondary 
functional HG is associated with unhealthy metabolic 
conditions, such as MetS, diabetes, and obesity [17]. 
3.  Obesity, metabolic syndrome and 
functional hypogonadism
Obesity is an expansion of  adipose tissue, and, 
therefore, an expansion of the body’s largest energy 
reservoir. According to this view and to the concept 
of “survival of the fittest”, obesity should represent 
an evolutionary advantage for the species. However, 
despite socioeconomic deprivation, we have nowadays 
more than sufficient food for most, and therefore little 
need to have an expanded energy reservoir. Hence, 
obesity is no longer considered a survival advantage 
but a source of obesity-associated comorbidities, which 
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chronically orchestrate unhealthy consequences as 
a function of lifetime expanding [18,19]. There is no 
doubt that secondary, functional HG is one of these 
unhealthy consequences. The association among obesi-
ty, and in particular visceral obesity, and other comor-
bidities, such as dyslipidemia, glucose impairment, and 
hypertension, is clustered in the concept of MetS. MetS 
is essentially a diagnostic category, helping physicians 
to identify subjects at major risk for metabolic and car-
diovascular complications. Actually, MetS is also deeply 
underpinned with secondary HG and erectile dysfunc-
tion (ED) [12,20]. 
AIM OF THE REVIEW
In this review, we will overview the effect of treat-
ments of functional HG alternative to pharmacological 
substitution with T or gonadotropins and their effects 
on sexual symptoms, including ED. It is important to 
note that several pharmacological treatments of either 
HG or ED are available and all are very efficacious, 
however, they are not the main topic of this review, 
as it has recently been covered elsewhere [2,21]. We 
will pay particular attention to obesity- and MetS-
associated HG, because of their prevalence, affecting 
more than 600 million adults worldwide. When pos-
sible, we used a meta-analytic analysis for scrutinizing 
results, because meta-analyses are considered as the 
highest level of evidence for evaluating interventions 
in healthcare. Meta-analyses have the advantage of 
extending the number of observations putting together 
the results of single trials, thus increasing the strength 
of the conclusions.














Stanik et al (1981) [24] Sepulveda, CA, USA BA 8 - - 4.2 13.9±3.4
Hoffer et al (1986) [25] Boston, MA, USA BA 4 34.0±7.0 33.1 0 13.0±1.0
Pasquali et al (1988) [26] Bologna, Italy BA 10 35.2±5.6 43.4±6.3 22.2 11.9
Strain et al (1988) [27] New York, USA BA 68 34.0±11.0 - 0 8.3±4.0
Leenen et al (1994) [28] Utrecht, The Netherlands BA 13 40.0±6.0 30.7±2.2 0 12.7±3.2
Pritchard et al (1999) [29] Laval, Canada BA 13 21.0±0.8 26.2±5.5 0 12.3±4.1
Kraemer et al (1999)a [30] Pennsylvania, USA RCT 12 39.7±6.6 33.1 0 15.9±7.7
Volek et al (2002) [31] Storrs, CT, USA BA 6 36.0±11.9 - 0 21.5±7.6
Mingrone et al (2002) [32] Rome, Italy RCT 54 - 47.8±8.8 0 -
Kaukua et al (2003) [33] Helsinki, Finland RCT 10 45.9±9.0 39.3±3.3 5.3 11.1±3.4
Niskanen et al (2004) [34] Kuopio, Finland BA 9 46.3±7.5 36.1±3.8 24.0 11.2±3.9
Heufelder et al (2009) [35] Berlin, Germany RCT 52 55.9±6.0 32.5±2.4 100 10.4±0.8
Reis et al (2010) [36] Saõ Paulo, Brazil RCT 104 42.2±10.5 54.0±6.7 0 11.7±5.1
Khoo et al (2010) [37] Adelaide, Australia CBA 8 49.6±11.0 34.4±4.0 38.8 20.2±6.9
Khoo et al (2011) [38] Adelaide, Australia RCT 52 62.3±5.9 35.6±4.8 100 13.9±3.3
Khoo et al (2011)b [38] Adelaide, Australia RCT 52 58.1±11.4 35.1±4.3 100 11.7±3.6
Khoo et al (2013) [39] Singapore, Singapore BA 90 40.8 32.7 - 12.2±5.7
Schulte et al (2014) [40] Kiel, Germany BA 13 44.0 42.7 0 6.9
Pop et al (2015) [41] New Brunswick, USA RCT 38 58±6 31.9±4.4 0 11.2±3.8
Armamento-Villareal et al (2016) [42] Houston, USA RCT 9 68.3±3.9 39.1±4.5 - 7.2±4.8
Ng Tang Fui et al (2016) [43] Melbourne, Australia RCT 49 54.3 37.5 20.4 6.8
Moran et al (2016) [44] Adelaide, Australia RCT 118 49.6 33.2 0 13.8
Moro et al (2016) [45] Padua, Italy RCT 34 29.9 26.6 - 21.3±16.9
Values are presented as mean only or mean±standard deviation. 
FU: follow-up, BMI: body mass index, DM: diabetes mellitus, TT: total testosterone, BA: controlled cohort before-and-after comparisons in the 
same group of patients, RCT: randomized controlled trials, CBA: controlled before-and-after study between two or more groups of participants 
receiving different interventions.
aLow calorie diet only group. bLow energy diet group. 
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EFFECT OF DIET-INDUCED WEIGHT 
LOSS ON FUNCTIONAL HYPOGONADISM
The clinical practice guidelines for medical care of 
patients with obesity from the American Association of 
Clinical Endocrinologists and the American College of 
Endocrinology [22] indicate that reducing total caloric 
intake should be the main component of any weight-
loss intervention, irrespective to the macronutrient 
composition. We previously meta-analyzed the effect of 
any low-calorie diet in 13 studies published until mid-
2012 and addressing the effect of caloric restriction 
on HPT [23]. We found that an average diet-induced 
weight loss of 9.8% was associated with a significant 
increase in total T (TT) of 2.8 nmol/L (1.68–4.07 nmol/
L) and 2.05 (0.93–3.16 nmol/L), when paired and non-
paired t-test models were applied. At that time, not 
enough studies were available to evaluate in a sub-
analysis the effect of diet-induced weight reduction 
on gonadotropin levels. However, when data from diet 
were combined with those from bariatric surgery (see 
below), we reported a significant weight loss-induced 
increase in luteinizing hormone (LH) (1.31 mU/L 
[0.80–1.82 mU/L]) and follicle stimulating hormone (1.79 
mU/L [1.28–2.30 mU/L]) [23]. Since that time, several 
new studies have been published. Nowadays, 22 stud-
ies evaluating the effect of low calorie diet on T levels 
and its metabolites are available [24-45]. These trials 
enrolled 567 patients with a mean age of 44.9 years, 
a mean body mass index (BMI) of 36.0 kg/m2, and a 
mean follow-up of 23 weeks. These trials differ in basal 
TT levels and type of diet applied (Table 1). For a more 
conservative approach, endpoint values of each param-
eter were evaluated in a non-paired fashion (non-paired 
analysis). Information on T levels at endpoint were 
available for 21 studies. Combining the results of those 
trials, low calorie diet results in a significant increase 
in TT levels at endpoint (Fig. 1A). We observed similar 
results when hormone binding globulin (SHBG) and 
calculated free T were considered (Fig. 1B, 1C, respec-
tively). Meta-regression analysis showed that a higher 
Δ-weight is associated with a higher T increase, mean-
ing that each 5 kg of weight reduction results in one 
nmol/L increases (Fig. 1D). The latter finding was con-
firmed in a multivariate regression analysis, after the 
adjustment for age and trial duration (adjusted r =-1.21; 
p<0.0001). 
EFFECT OF BARIATRIC SURGERY-
INDUCED WEIGHT LOSS ON 
FUNCTIONAL HYPOGONADISM
So far, five systematic meta-analyses [11,23,46-48] 
have been published concerning changes in sex hor-
mone levels upon bariatric surgery. Despite differences 
in the number of studies analyzed and in the inclusion 
criteria for the study selection (Table 2), all the meta-
analyses found a significant, sustained increase in TT 
and free T after bariatric surgery, as compared with 
the pre-surgical values (Fig. 2A). The mean increase in 
T was comparable in all the available meta-analyses 
ranging from 8 to 10 nmol/L for TT and from 75 to 90 
pmol/L for free T (Fig. 2B). A significant increase in 
SHBG and gonadotropins was also consistently found 
in all these meta-analyses (Fig. 2C–2E). Total estradiol 
was significantly decreased after bariatric surgery, 
with a mean reduction of about 20 pmol/L, as docu-
mented by most meta-analyses, except for the earliest 
one [11] which found a decline of around a half (Fig. 
2F).
EFFECT OF DRUG-INDUCED 
WEIGHT LOSS ON FUNCTIONAL 
HYPOGONADISM
Only one study investigated the effect of an anti-
obesity drug, i.e., liraglutide, on HPT in obese hypogo-
nadal men with sexual symptoms and poor responses 
to lifestyle measures [49]. Liraglutide is a glucagon-like 
peptide-1 receptor agonist first approved for treatment 
of T2DM at doses up to 1.8 mg/d and later on approved 
for weight loss at a higher dosage (3.0 mg/d). In this 
trial [49], effects of liraglutide on TT levels were com-
pared to those of TTh (1% T gel) in a 16-week study 
with 15 subjects enrolled per arm. Liraglutide, but not 
TTh, induced a 6% reduction in weight. Both treat-
ments ameliorated sexual symptoms and increased 
significantly TT, although the increase was more evi-
dent with T gel (5.9 vs. 2.6 nmol/L with liraglutide). As 
expected, TTh further reduced LH levels, whereas lira-
glutide marginally improved it (0.7 mU/L). 
EFFECT OF PHYSICAL EXERCISE ON 
FUNCTIONAL HYPOGONADISM
Overall, 8 studies evaluated the effect of physical 
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exercise on T levels [42,50-56]. These trials enrolled 202 
patients with a mean age 51.8 years, mean BMI of 28.5 
kg/m2, and mean follow-up of 15 weeks. Trials differ in 
basal TT levels and physical exercise protocol (Table 
3). For a more conservative approach, endpoint TT val-
ues of each parameter were evaluated in a non-paired 
fashion (non-paired analysis). Combining the results of 
those trials, physical exercise resulted in a significant 
increase in TT levels at endpoint (Fig. 3A). In order to 
evaluate the major determinants of the increase of TT 
after physical exercise (Δ-TT), a multivariate regres-
sion analysis was performed using (Δ-TT) as the depen-
dent variable and age, trial duration as well as percent 
reduction of weight (Δ-weight) after physical exercise 
as putative predictors. The standardized coefficients 
are shown in Fig. 3B and suggest that a greater weight 
loss and a longer trial duration are significantly as-
sociated with an increase in TT levels, independently 
Fig. 1. Weighted differences (with 95% confidence interval [CI]) of mean total testosterone (TT; A), calculated free testosterone (B), sex hormone 
binding globulin (C) and before and after weight loss. aLow calorie diet only group. bLow energy diet group. (D) Influence of Δ-weight loss on TT 
weighted mean differences before and after low calorie diet as derived from meta-regression analysis.
https://doi.org/10.5534/wjmh.190061
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of age. Interestingly, the analysis also shows that for 
equal weight change, a greater improvement in TT lev-
els is obtained in older men.
EFFECT OF LIFESTYLE CHANGE ON 
SEXUAL SYMPTOMS
Considering that sexual complaints are the main 
symptoms related to LOH – and most probably to 
functional HG – it is important to examine the effect 
of lifestyle modifications on them, and, in particular, 
Fig. 1. Continued.
Table 2. Available meta-analyses evaluating the effects of bariatric surgery on testosterone levels 
Study No. of trial No. of patient Main inclusion criteria
Corona et al (2013) [23] 11 262 Studies comparing testosterone levels before and after bariatric surgery
Corona et al (2015) [11] 15 398 Studies comparing testosterone levels before and after bariatric surgery
Escobar-Morreale et al  
(2017) [46]
7 382 Studies showing data on prevalence of obesity-associated secondary hypogonadism 
among patients undergoing to bariatric surgery
Wen et al (2018) [47] 23 654 Studies reporting sexual function and at least one sex hormone level with a follow-up 
time of at least 6 months
Lee et al (2019) [48] 28 1,022 Studies evaluating the effect of bariatric surgery on sex hormones or sperm parameters
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on ED. However, this is not the main topic of the pres-
ent review, even because this issue was extensively 
covered by two recent meta-analysis [57,58]. One of 
them examined the effect of different lifestyle factors 
in population-based research. Cigarette smoking, high 
alcohol intake, and lack of physical activity all have 
deleterious effects on erectile function [58]. However, 
the most impressive results were observed for regular 
physical activity, which reduced the odds ratio for ED 
by 50% [58]. In addition, this effect was apparent in al-
most all the individual studies scrutinized [58]. Another 
meta-analysis investigates the effect of intervention 
with any physical activity on ED patients in random-
ized controlled trails, having, as an end-point, variation 
in ED scoring, as evaluated through the International 
Index of Erectile Function erectile function domain 
(IIEF-EFD). They found that on average physical activ-
ity increased IIEF-EFD by almost 4 points, an effect 
that is not very far from the 5 point increase – as eval-
uated in the meta-analysis – by the most recent phos-
phodiesterase type 5 inhibitor (PDE5i) on the market, 
avanafil [59].
MECHANISM OF ACTION OF 
PHYSICAL ACTIVITY ON FUNCTIONAL 
HYPOGONADISM AND ITS RELATED 
ERECTILE DYSFUNCTION
Human data derived from intervention trials aimed 
at investigating the effect of changing lifestyle on 
functional HG indicate that reducing caloric intake 
(diet or bariatric surgery) or increasing caloric expen-
diture (physical activity) improve TD. Overall, the data 
summarized above suggest that they are efficacious in 
restoring an altered HPT axis, as often observed in sev-
eral metabolic conditions, including obesity and MetS. 
In particular, a recent meta-analysis indicates that 
consistent aerobic endurance exercise is the most effec-
tive strategy for preventing ED [58], beside increasing 
T levels. However, human data does not offer insights 
Corona et al (2013) [23]
Corona et al (2015) [11]
Escobar-Morreale et al (2017) [46]
Wen et al (2018) [47]
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Fig. 2. Summary of the results obtained by available the meta-analyses, which evaluated the effects of bariatric surgery on sex hormones, go-
nadotropins, and SHBG. SHBG: sex hormone binding globulin, LH: luteinizing hormone, FSH: follicle stimulating hormone.
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on how changing lifestyle acts in ameliorating TD and 
its associated symptoms.
1.  Establishment of a rabbit model of 
metabolic syndrome-associated 
hypogonadotropic hypogonadism
In the last ten years, we have developed an animal 
(rabbit) model of MetS by feeding rabbits a high fat 
diet (HFD) [60]. This animal model shares with the hu-
man phenotype several basic characteristics of MetS, 
i.e., hypertension, glucose intolerance, dyslipidemia, and 
increased visceral fat [60]. In addition, these rabbits 
show a MetS factor-dependent hypogonadotropic HP 
and ED [60]. Fig. 4A, shows the HFD-dependent decline 
in circulating T in a large number of rabbits. The same 
Fig. 4B shows that in MetS rabbits not only T levels 
were reduced but also LH levels are, at levels not sta-
tistically different from those induced by impairing 























I: 60% of maximal effort
RCT 12 21.00±2.00 20.99±3.35 18.46±5.62
Arazi et al (2013)  
[51]
Rasht, Iran 8 D: 60’
F: 3/wk
T:  anaerobic floor exercises 
(resistance training)
I: moderate
CBA-S 8 49.7±2.1 26.3 11.76±0.96
Hayes et al (2015)  
[52]
Hamilton, UK 28 D: 150’
F: minimum 2/wk
T: aerobic exercise
I: moderate and vigorous
CBA 28 63±5 29.7 13.25±6.15
Kumagai et al  
(2015) [53]
Tsukuba, Japan 44 D: 40–60’
F: 3/wk
T:  aerobic (walking and  
jogging)
I:  gradually from light to 
hard
BA 12 51.0±13.3 29±6.6 12.3±6.0
Armamento-Villareal 
et al (2016)a [42]




RCT 52 68.7±1.8 35.1±5.2 9.28±4.34
Kumagai et al  
(2016) [54]
Tsukuba, Japan 41 D: up to 90’
F: 4–7/wk
T:  aerobic (walking and/or 
jogging)
I: moderate and vigorous
CBA 12 49.2±6.0 29.0±3.0 12.2±6.04
Hayes et al (2017)  
[55]
Hamilton, UK 22 D: 150’
F: every 5 days
T: bicycle ergometry
I: 40% of maximal effort
CBA 6 - - -
Kumagai et al  
(2018) [56]
Tsukuba, Japan 28 D+F: at least 150’/wk
T:  aerobic (walking and/
or light jogging+aerobic 
exercises at home)
I: moderate to vigorous
CBA-S 12 50.0±6.4 27.4±2.1 15.4±7.4
Values are presented as mean only or mean±standard deviation. 
FU: follow-up, BMI: body mass index, TT: total testosterone, D: duration of each session of physical activity, F: frequency of physical activity, T: type 
of physical activity, I: intensity of physical activity, RCT: randomized controlled trials, CBA: controlled before-and-after study between two or more 
groups of participants receiving different interventions, BA: controlled cohort before-and-after comparisons in the same group of patients.
aExercise only group. 
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Fig. 3. (A) Weighted differences (with 95% confidence interval [CI]) of mean total testosterone (TT), after physical activity. aExercise only group. (B) 
Change in TT (dependent variable) as a function of weight change, exercise duration and age (independent variables) as derived from a multivari-
ate linear regression weighted for trial participants. Data derive from the meta-analysis of the available trials on the effect of physical exercise on 
testosterone levels. The independent variables were transformed as z-values (standardized parameters). The value corresponding to 1 standard 
deviation is reported below each independent variable.
Fig. 4. Effects of physical exercise on hormonal circulating levels in regular diet (RD) and high fat diet (HFD) rabbits. Testosterone (A) and lutein-
izing hormone (LH; B) plasma levels were measured in rabbits fed a RD or a HFD with and without physical exercise (PhyEx), according to a previ-
ous protocol [62]. Results obtained in rabbits treated with the gonadotropin-releasing hormone (GnRH) analog triptorelin [60] were also shown, 
for comparison. Numbers of experimental observations are reported below each group. Statistical analysis between groups was performed with 
Kruskal–Wallis and post-hoc Mann–Whitney non-parametric tests. p-values are reported in each panel. NS: non-significant.
https://doi.org/10.5534/wjmh.190061
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LH secretion through gonadotropin-releasing hormone 
(GnRH) analog administration. Hence, HFD induced 
a genuine hypogonadotropic HP. We have previously 
demonstrated that the MetS-induced hypogonadotropic 
HP was associated with a peculiar inflammation of 
the medial preoptic area (MPO) of the hypothalamus, 
where GnRH neurons are located, characterized by an 
increased expression of cyclooxygenase-2 and macro-
phage markers [61,62]. Interestingly, in MPO of MetS 
rabbits, immunopositivity for GnRH was decreased, 
along with an altered expression of the main neu-
rotransmitters regulating GnRH secretion, as Kiss1 
and its receptor (Kiss1R) [60-62]. Fig. 5 and 6 show im-
munostaining for GnRH and Kiss1R in hypothalamic 
sections from rabbits fed a regular diet (RD; Fig. 5A, 
6A) and in MetS-animals fed a HFD (Fig. 5B, 6B). We 
previously reported that, upon HFD, genes coding 
inhibitory factors for GnRH were increased, as well 
as neuropetide Y and prodynorphin, along with their 
cognate receptors [62]. In addition, we also reported an 
increased expression in MPO of estrogen receptor (ERβ 
and GPR30), which – in the male hypothalamus – me-
diates a negative feedback on GnRH [61,62]. Finally, in 
MPO of MetS rabbits several genes related to glucose 
transporter (GLUT) #1–4 and metabolism (insulin 
receptor substrate 1) were up-regulated [61,62]. MetS-
associated HG was also associated with symptoms and 
signs of TD, as decreased prostate weight and ED [61,62]. 
In MetS animals, ED was characterized by impaired 
responsiveness to acetylcholine (Ach) and PDE5i, due 
to an impairment in nitric oxide formation and action 
[60,62]. Interestingly, we previously reported that T ad-
ministration was able to restore sensitivity to Ach and 
PDE5i [60].
2.  Effect of physical exercise in a rabbit 
with metabolic syndrome-associated 
hypogonadotropic hypogonadism
To evaluate the effect of physical activity on MetS-
induced HG and ED, RD and MetS rabbits were 
exercise-trained to run on a treadmill for 12 weeks 
(RD+PhyEx and HFD+PhyEx). As mentioned before, 
HFD rabbits showed typical metabolic and cardiovas-
cular features of MetS along with hypogonadotropic 
HG. Within the testis, the MetS condition down regu-
lated, in a stepwise fashion, all the steroidogenic en-
zymes leading to T synthesis, along with an increase 
in fibronectin expression. PhyEx completely restored T 
and LH plasma levels, prostate weight and GnRH im-










































Fig. 5. Gonadotropin-releasing hormone (GnRH) immunohistochemical analysis in experimental rabbits. (A) Representative images of coronal hy-
pothalamic sections, including the preoptic region lining the 3rd ventricle (3V). (B) Quantification of GnRH-positive cells, as calculated by count-
ing at least ten fields of three independent experiments (mean±standard error; n=3 for each group; ap<0.001 vs. RD, bp<0.001 vs. HFD, cp<0.001 
vs. RD+PhyEx). Scale bar 50 μm. RD: regular diet, HFD: high fat diet, PhyEx: physical exercise.
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the preoptic area [62]. All the aforementioned HFD-in-
duced increase in genes related to inflammation, estro-
gen signaling, and glucose metabolism in the hypothal-
amus were significantly reduced in HFD+PhyEx. In 
particular, in the hypothalamus, PhyEx increased Kiss 
1 and decreased orexigenic and GnRH-inhibiting fac-
tors (dynorphin and its receptors OPRD1 and OPRK1), 
whereas it increased anorexigenic ones (proopiomelano-
cortin). PhyEx restored Kiss1 receptor immunostaining, 
which resulted decreased by HFD (Fig. 6B). Within the 
testis, PhyEx normalized fibronectin expression and 
increased genes related to T formation (17βHSD3) and 
metabolism (5α-reductase 1) [62]. Accordingly, PhyEx 
increased the ratio of androstenedione to T concentra-
tion within the testis, which resulted downregulated by 
HFD [62]. Corpora cavernosa (CC) strips from HFD rab-
bits showed a hypo-responsiveness to Ach and electri-
cal field (EF) stimulation. In addition, sildenafil action 
on EF- or sodium nitroprusside-induced relaxation was 
also impaired in HFD CC. PhyEx reverted all these 
alterations. In CC extracts, several genes related to 
NO formation (DDAH1) and signaling (GCSa1, GCSb1, 
PDE5, PKG) were up-regulated by PhyEx, along with 
those involved in smooth muscle differentiation (SM22, 
αSMA) and androgen action (AR, STAMP2). 
In conclusion, in this experimental model, endurance 
training (PhyEx) completely reverted MetS-induced 
hypogonadotropic HP and ED, having beneficial effects 
on the HPT axis and on the penis. In the hypothala-
mus, PhyEx reduced HFD-induced inflammation, in 
the testis, it reduced fibrosis and, in the penis, it allows 
a better relaxation and response to sildenafil. Hence, 
according to preclinical data aerobic exercise training 
can be considered an interesting strategy to combat 
MetS-associated HP and ED. 
CONCLUSIONS
Functional HG is by far the most common condi-
tion determining, in the adult male, a TD that can be 
also symptomatic, having sexual complains – and in 
particular ED – as the most characteristic symptoms. 
The distinction between a functional and an organic 
form of HG is, in some ways, captious because, as dem-
onstrated in our preclinical model, even diet-induced 
hypogonadotropic HG is associated with distinct, or-
ganic alterations within the hypothalamus, the testis 
and the penis [60-62]. However, the main advantage 
of considering a functional form of HG is that this is 










































Fig. 6. Immunohistochemical analysis of Kiss1 receptor (Kiss1R) in rabbit hypothalamus. (A) Representative images of coronal hypothalamic sec-
tions, including the preoptic region lining the 3rd ventricle (3V). (B) Quantification of Kiss1R-positive cells, as calculated by counting at least ten 
fields of three independent experiments (mean±standard error; n=3 for each group; ap<0.001 vs. RD, bp<0.001 vs. HFD, cp<0.05 vs. RD+PhyEx). 
Scale bar 50 μm. RD: regular diet, HFD: high fat diet, PhyEx: physical exercise.
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cians should strongly encourage subjects meeting the 
criteria of functional HG to adapt all the reasonable 
strategies to remove/mitigate the known conditions 
underlying functional HP, including MetS and obesity. 
Considering that combating obesity is not an easy task, 
the first step is to create a supportive environment to 
promote healthy living behaviors that prevent its ap-
pearance. However, when obesity is already present, 
change in lifestyle is imperative. Therapeutic diets 
and behavioral modifications are reasonable (but not 
often successful) clinical strategies, even for protect-
ing against obesity-associated HG, as demonstrated by 
the meta-analyses also reported here. Physical activ-
ity, integrated within daily life, is another important 
option not only to induce a weight change but also 
for achieving a long-term weight management and 
overall health enhancement. In particular, according 
to recommendations (https://health.gov/paguidelines/
second-edition/10things/), adults need at least 150 to 
300 minutes of moderate-intensity aerobic activity each 
week, although any amount of physical activity has 
some health benefits. We reported here, by meta-ana-
lyzing available studies, that physical exercise is able 
to increase T levels, in particular in older individuals, 
with a benefit that is proportional to the amount and 
duration of the activity. Hence, we should encourage 
obese individuals in developing the skills necessary 
for physical activity and exercise. An open question is 
whether obese, hypogonadal individuals have the skills 
to progress safely and effectively along the continuum 
of changing their lifestyle. Physical limitations, includ-
ing reduced muscle mass and increased fat mass, along 
with low self-confidence, also due to the sexual prob-
lems, might limit the propensity to increase physical 
activity and dieting. It is therefore conceivable that a 
short-term TRT trial, by improving muscle mass [63-
66] and sexual problems [66,67], will help obese patients 
with HG to overcome the overfed, inactive state to 
become physically and psychologically ready for chang-
ing their lifestyle. In our opinion, this strategy could be 
more successful. 
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